RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Protagonist Therapeutics - Stock

Protagonist Therapeutics ROA 2024

Protagonist Therapeutics ROA

-0.22

Ticker

PTGX

ISIN

US74366E1029

WKN

A2AP32

In 2024, Protagonist Therapeutics's return on assets (ROA) was -0.22, a -57.08% increase from the -0.51 ROA in the previous year.

Protagonist Therapeutics Aktienanalyse

What does Protagonist Therapeutics do?

Protagonist Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel peptide therapies. The company was founded in 2002 and is headquartered in Newark, California. The history of Protagonist Therapy began with the discovery of a new type of molecules called peptides, which can be used as potential drugs for various diseases. This discovery was the result of years of research and collaboration between academics and leading pharmaceutical companies. Protagonist Therapeutics' business model is focused on developing and distributing new peptide therapies in the pharmaceutical industry. The company works closely with leading academics and biotechnology companies to advance its research and development projects. Protagonist Therapeutics is divided into several divisions focusing on different therapeutic areas. These include gastrointestinal diseases, immunology, and oncology. Each division works on developing new peptide therapies specifically tailored to their respective therapeutic areas. One example of a product from Protagonist Therapeutics is PTG-300, which was developed for the treatment of iron deficiency anemia. PTG-300 is a synthetic peptide that promotes increased iron uptake in the body to combat iron deficiency. Another product from Protagonist Therapeutics is PTG-200, which was developed for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. PTG-200 is a peptide that blocks the action of certain enzymes that amplify inflammation in the intestine. Overall, Protagonist Therapeutics aims to establish itself as a leading provider of peptide therapies in the pharmaceutical industry. The company has a strong financial foundation, including a successful IPO in 2016, and is continuously working on developing new products to expand and grow the company. Protagonist Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Protagonist Therapeutics's Return on Assets (ROA)

Protagonist Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Protagonist Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Protagonist Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Protagonist Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Protagonist Therapeutics Stock

What is the Return on Assets (ROA) of Protagonist Therapeutics this year?

The Return on Assets (ROA) of Protagonist Therapeutics is -0.22 undefined this year.

What was the ROA of Protagonist Therapeutics compared to the previous year?

The ROA of Protagonist Therapeutics has increased by -57.08% compared to the previous year.

What consequences do high ROA have for investors of Protagonist Therapeutics?

A high ROA is advantageous for investors of Protagonist Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Protagonist Therapeutics?

A low ROA can be unfavorable for investors of Protagonist Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Protagonist Therapeutics affect the company?

An increase in ROA of Protagonist Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Protagonist Therapeutics impact the company?

A reduction in the ROA of Protagonist Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Protagonist Therapeutics?

Some factors that can influence the ROA of Protagonist Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Protagonist Therapeutics important for investors?

The ROA of Protagonist Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Protagonist Therapeutics take to improve ROA?

To improve ROA, Protagonist Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Protagonist Therapeutics pay?

Over the past 12 months, Protagonist Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protagonist Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protagonist Therapeutics?

The current dividend yield of Protagonist Therapeutics is .

When does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protagonist Therapeutics?

Protagonist Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protagonist Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protagonist Therapeutics located?

Protagonist Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protagonist Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protagonist Therapeutics from 6/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/30/2024.

When did Protagonist Therapeutics pay the last dividend?

The last dividend was paid out on 6/30/2024.

What was the dividend of Protagonist Therapeutics in the year 2023?

In the year 2023, Protagonist Therapeutics distributed 0 USD as dividends.

In which currency does Protagonist Therapeutics pay out the dividend?

The dividends of Protagonist Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Protagonist Therapeutics

Our stock analysis for Protagonist Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protagonist Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.